S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

PetVivo Stock Forecast, Price & News

0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $13.50
50-Day Range
MA: $7.75
52-Week Range
Now: $13.50
Volume414 shs
Average Volume7,473 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
PetVivo Holdings, Inc., a biomedical device company, engages in the licensing and commercializing medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products includes 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.


Overall MarketRank

0.38 out of 5 stars

Medical Sector

1687th out of 1,923 stocks

Medical Devices Industry

16th out of 17 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical Devices
Current SymbolOTCMKTS:PETV



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PETV News and Ratings via Email

Sign-up to receive the latest news and ratings for PETV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PetVivo (OTCMKTS:PETV) Frequently Asked Questions

How has PetVivo's stock price been impacted by COVID-19?

PetVivo's stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PETV stock has increased by 3,650.0% and is now trading at $13.50.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than PetVivo?

Wall Street analysts have given PetVivo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PetVivo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were PetVivo's earnings last quarter?

PetVivo Holdings, Inc. (OTCMKTS:PETV) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.04) EPS for the quarter. The company earned $0.01 million during the quarter.
View PetVivo's earnings history

Who are some of PetVivo's key competitors?

Who are PetVivo's key executives?

PetVivo's management team includes the following people:
  • Mr. John Lai, CEO, Pres & Director (Age 58, Pay $4.8k)
  • Mr. John Michael Carruth, Chief Financial Officer (Age 31, Pay $100k)
  • Mr. John F. Dolan, Gen. Counsel, Sec. & Exec. Director (Age 55, Pay $2.28k)
  • Dr. David B. Masters, Director of Science & Technology and Director (Age 62)
  • Mr. Gary DeMel, Exec. VP of Bus. Devel. (Age 63)
  • Mr. Randy Wenthold, Chief Science Officer

What is PetVivo's stock symbol?

PetVivo trades on the OTCMKTS under the ticker symbol "PETV."

How do I buy shares of PetVivo?

Shares of PETV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PetVivo's stock price today?

One share of PETV stock can currently be purchased for approximately $13.50.

What is PetVivo's official website?

The official website for PetVivo is www.petvivo.com.

How can I contact PetVivo?

The company can be reached via phone at 952-681-7913.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.